Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury

Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. doi: 10.1073/pnas.0402090101. Epub 2004 Jul 28.

Abstract

The chemokine CXC ligand 8 (CXCL8)/IL-8 and related agonists recruit and activate polymorphonuclear cells by binding the CXC chemokine receptor 1 (CXCR1) and CXCR2. Here we characterize the unique mode of action of a small-molecule inhibitor (Repertaxin) of CXCR1 and CXCR2. Structural and biochemical data are consistent with a noncompetitive allosteric mode of interaction between CXCR1 and Repertaxin, which, by locking CXCR1 in an inactive conformation, prevents signaling. Repertaxin is an effective inhibitor of polymorphonuclear cell recruitment in vivo and protects organs against reperfusion injury. Targeting the Repertaxin interaction site of CXCR1 represents a general strategy to modulate the activity of chemoattractant receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allosteric Regulation / physiology*
  • Animals
  • Binding Sites
  • Humans
  • Inflammation / metabolism*
  • Liver Diseases / pathology
  • Models, Molecular
  • Protein Conformation / drug effects
  • Rats
  • Receptors, Interleukin-8A / antagonists & inhibitors*
  • Reperfusion Injury / drug therapy
  • Reperfusion Injury / prevention & control*
  • Signal Transduction / drug effects
  • Structure-Activity Relationship
  • Sulfonamides / antagonists & inhibitors
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use

Substances

  • Receptors, Interleukin-8A
  • Sulfonamides
  • reparixin